ASH 2021

Conference Coverage

First-Line Axi-Cel Appears Effective in High-Risk Large B-Cell Lymphoma

At a median follow-up of 15.9 months, the median duration of response was not reached.

Smartphone App Helps Guide Use of CAR T-Cell, BiTE Therapy

The “myTcell” app is expected to be released in the United States in 2022.

MDS/CMML With KMT2A Rearrangements ‘Should Be Classified as AML’

There was no difference in overall survival between patients with MDS/CMML and those with AML.

Triplet Improves Outcomes in Older Patients With FLT3-Mutated Acute Myeloid Leukemia

Response rates and overall survival were superior in the triplet group.

Anakinra Can Prevent Severe CRS, ICANS After CAR T-Cell Therapy

There was 1 case of grade 3 CRS and 1 case of grade 4 CRS.

Novel Agents Lead to Changes in Therapeutic Strategies and Sequencing for CLL

Data were analyzed from patients diagnosed with CLL between 2000 and 2020 from 77 institutions affiliated with the ERIC.

Reinfusion of CAR-T Cells May Prevent Relapse in Acute Lymphoblastic Leukemia

The findings of this study prompted a change in clinical practice.

Brexu-Cel Deemed Safe, Effective for Mantle Cell Lymphoma in Real-World Study

Outcomes were similar to those seen in the ZUMA-2 trial.

Acalabrutinib Effective for Relapsed/Refractory CLL at 3 Years

The findings support the use of acalabrutinib in patients with relapsed/refractory CLL, including those with high-risk features.

Black Patients Less Likely to Receive Novel Agents as First-Line CLL Therapy

Investigators revealed unequal access to novel agents when comparing Black and White patients with CLL.

Lymphadenopathy in CLL Patients Predicts Richter’s Syndrome Risk After Ibrutinib

The retrospective study included 559 patients who had received ibrutinib for CLL, of whom 179 progressed according to iwCLL criteria.

Black AYAs With AML Have Worse Outcomes Than White Counterparts

The disparity was driven by patients aged 18-29 years.

Ibrutinib Plus Venetoclax Produces Superior uMRD Responses in CLL

Researchers presented updated findings from the GLOW trial.

Gilteritinib Does Not Improve Survival in FLT3-Mutated AML

Most outcomes were similar for patients who received gilteritinib plus azacitidine and those who received azacitidine alone.

Cardiac Events Seen in One-Fifth of AML Patients on Venetoclax Plus HMAs

Most events occurred during treatment cycles 1 and 2.

No EFS Benefit With Second-Line Tisa-Cel in Relapsed/Refractory Non-Hodgkin Lymphoma

The median event-free survival was 3 months in both treatment arms.

Third COVID-19 Vaccine Dose Boosts Seroconversion Rate in CLL Patients

Vaccine responses were evaluated after dose 1 for 158 CLL patients, after dose 2 for 506 patients, and after dose 3 for 66 patients.

Hospitalization, ED Visits Highest in First Month After CAR T-Cell Infusion

Sixty-seven percent of rehospitalizations occurred within the first month of CAR T-cell infusion.

Women With AML Have Worse Outcomes With Gemtuzumab Ozogamicin

GO plus cytarabine was no more effective than standard chemotherapy and appeared particularly detrimental for women.

Parsaclisib Elicits ‘Rapid and Durable’ Responses in Relapsed/Refractory Follicular Lymphoma

The median duration of response was 14.7 months.